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Background:  Compared to unfractionated heparin (UFH), bivalirudin is associated with similar efficacy and improved safety in patients 
undergoing percutaneous coronary intervention. However, the role of direct thrombin inhibitors in peripheral vascular interventions is not 
well defined.
methods:  We compared the incidence of in-hospital access site complications and discharge status among patients in the multicenter, 
prospective Vascular Quality Initiative Registry who underwent peripheral vascular intervention between August 2007 and January 2014 
using bivalirudin or UFH. Propensity score matching was used to obtain a balanced cohort of 1,524 patients in each treatment group.
results:  Patients treated with bivalirudin had a significantly lower incidence of access site hematomas (2.4% versus 3.9% p=0.018), 
shorter postprocedural hospitalization (1.0 vs. 1.2 days, p<0.001) and higher rates of discharge to a nursing home or rehabilitation center 
rather than home (7.61% vs. 9.73%, p=0.034) when compared with heparin-treated patients. The incidence of in-hospital access site 
occlusion, distal embolization and mortality did not differ significantly between groups.
conclusion:  Bivalirudin was associated with lower rates of access site hematomas, shorter length of stay and improved discharge status 
compared with heparin during hospitalization for peripheral vascular intervention. Randomized comparisons of these agents are needed to 
confirm these findings.
table: Clinical Outcomes by Treatment Group Among Propensity-Matched Cohort
Heparin (n=1524) Bivalirudin (n=1524) P value Odds Ratio(95% CI)
Access site hematoma 60 (3.9%) 37 (2.4%) 0.018 0.607 (0.401 - 0.920)
Access site occlusion 5 (0.3%) 4 (0.3%) 0.735 0.797 (0.214 - 2.973)
Distal embolization 19 (1.3%) 12 (0.8%) 0.206 0.712 (0.315 - 1.605)
Discharge to nursing
home/rehabilitation 148 (9.73%) 116 (7.61%) 0.034 0.760 (0.590 - 0.980)
In-hospital death 12 (0.79%) 5 (0.33%) 0.079 0.404 (0.142 - 1.150)
Postprocedural LOS, mean days ± SD (range) 1.2±1.7 (0-7) 1.0±1.2 (0-7) <0.001**
LOS = length of stay, SD = standard deviation
* Compared with patients discharged home
** Unequal variance
